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wearing off and dyskinesia, a difficulty or distortion in performing voluntary movements (Hauser, 2009; Hornykiewicz, 2002) . Thus, current treatments improve the motor symptoms and quality of life for patients during the early stages of PD. Several researches in PD have been carried out using PD animal model. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-injected mouse model is one of the most well-validated PD models. MPTP was found in a byproduct of an illegal synthetic drug (Langston, Ballard, Tetrud, & Irwin, 1983 ) and its metabolite MPP + which is preferentially 
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transported to dopaminergic neurons through dopamine transporter causes permanent symptoms of PD by destroying dopaminergic neurons in the SNc (Hayley et al., 2004) . Inflammatory responses including microglial and subsequent increase in GFAP level in astrocytes (astroglial activation) are implicated to contribute to neuronal degeneration in PD (Niranjan, 2014) . This harmful inflammatory process could amplify neurodegeneration and accelerate progression of PD. Collapsin response mediator protein 2 (CRMP2) was originally identified as a molecule involved in semaphorin3A (Sema3A) signaling (Goshima, Nakamura, Strittmatter, & Strittmatter, 1995) . CRMP family comprises at least five members and all of the five CRMPs are expressed mainly in the developing nervous system and may play a role in neuronal development (Byk, Ozon, & Sobel, 1998; Hamajima et al., 1996; Wang & Strittmatter, 1996) . Sema3A induces the phosphorylation of CRMP2 at Ser-522 by cyclin-dependent kinase 5 (Cdk5) followed by the phosphorylation at Thr-509, Thr-514 and Ser-518 by glycogen synthase kinase-3β (GSK3β) and thereby promotes growth cone collapse (Uchida et al., 2005; Yoshimura et al., 2005) . Recently, it is demonstrated that Akt/GSK3β/CRMP2 pathway is involved in axon degeneration of cultured dopaminergic neurons induced by MPP+, the active metabolite of MPTP (Fang et al., 2014) . Thus, we here investigated the role of CRMP2 phosphorylation in axon degeneration in vivo PD model. In present study, we used Crmp2KI/KI mice where the phosphorylation of Cdk5 and GSK3β were eliminated . Our experimental results indicate that suppression of CRMP2 phosphorylation may be a novel therapeutic target for PD.
| RESULTS
| Enhanced level of CRMP2 phosphorylation in dopaminergic neuron in SNc after MPTP injection
To investigate the role of CRMP2 phosphorylation in MPTPinduced PD mouse model, we first examined the changes in CRMP2 phosphorylation level after MPTP injection in dopaminergic neurons of SNc. After sub-acute paradigm MPTP injection (inject once a day for 2 days and kill 1 day after the last injection), we carried out immunohistochemical analysis with anti-TH antibody (the marker for dopaminergic neuron) and a specific antibody for phosphorylated CRMP2 at or phosphorylated CRMP2 at Thr-509 (pCRMP2-T509). We found increment of pCRMP2-S522 immunoreactivity in TH-positive neurons in MPTP-injected mice (Figure 1a ,b, p < 0.05, n = 4 mice for MPTP−, n = 3 mice for MPTP+), but no change of pCRMP2-T509 one (Figure 1c,d , p = 0.92, n = 3 mice for each condition).
Because antibody against pCRMP2-S522 may react with phospho-CRMP1-S522, we carried out immunohistochemical analysis with an antibody for phosphorylated CRMP2 at Ser-522 using samples from Crmp2KI/KI mice. We found no significant staining (Supporting information Figure S1 ), suggesting that the staining with an antibody for phosphorylated CRMP2 at Ser-522 mainly detected the phosphorylated CRMP2 at Ser-522.
2.2 | MPTP-induced nigral-striatal pathway degeneration was reduced in Crmp2KI/KI mice Given the increased phosphorylation of CRMP2 phosphorylation observed after MPTP injection, we next examined the effect of the suppression of CRMP2 phosphorylation on the survival of dopaminergic neurons. For this purpose, we used Crmp2KI/KI mice in which CRMP2 phosphorylation by Cdk5 and GSK3β was eliminated by replacing Ser-522 with an Ala residue . We conducted immunolabeling by using anti-TH antibody to measure the number of dopaminergic cells in the SNc after sub-chronic MPTP injection. The number of dopaminergic cells in the SNc decreased significantly in both Crmp2+/+ mice and Crmp2KI/ KI mice after MPTP injection (Figure 2a ,b, p < 0.0001, n = 4 mice for Crmp2+/+ MPTP−, Crmp2+/+ MPTP+ and Crmp2KI/KI MPTP−, n = 5 mice for Crmp2KI/KI MPTP+). This result suggests that inhibition of CRMP2 phosphorylation could not suppress the dopaminergic cell death.
We next examined by immunohistochemistry the density of dopaminergic input to the striatum arising from the nigrostriatal pathway. MPTP injection induced a 37.7% ± 6.7% reduction in TH immunoreactivity in the striatum of Crmp2+/+ mice (Figure 2c ,d, p < 0.05, n = 4 mice). However, no significant reduction in TH immunoreactivity with MPTP was observed in Crmp2KI/KI mice (Figure 2c ,d, p = 0.71, n = 3 mice). We also examined TH protein levels in the striatum by Western blot analysis. A significant reduction in TH was observed in the striatum of Crmp2+/+ mice after MPTP injection (Figure 2e ,f, p < 0.01, n = 4 mice). However, this reduction was suppressed in Crmp2KI/KI mice ( Figure 2e ,f, p = 0.09, n = 4 mice). These results indicate that the CRMP2 phosphorylation at S522 likely contributes to TH-positive dopaminergic fibers loss in the striatum after sub-chronic MPTP injection.
| Inhibition of CRMP2 phosphorylation suppressed microglial activation after MPTP injection
To determine the role of CRMP2 phosphorylation in inflammatory responses in MPTP-injected PD model mouse, we conducted immunolabeling with anti-Iba1 antibody, a marker for microglia, and anti-GFAP antibody, a marker | Genes to Cells
for astrocytes increased in astrogliosis. First, we examined the number of Iba1-positive activated microglia around the SNc after sub-chronic MPTP injections. There was a 60.7% ± 8.4% increase in the number of activated microglia that was observed in Crmp2+/+ mice after subchronic MPTP injections (Figure 3a ,b, p < 0.001, n = 6 mice). This increase was attenuated to 11.4% ± 11.3% in Crmp2KI/KI mice ( Figure 3a ,b, p = 0.83, n = 5 mice). (f) Quantification of each band intensity measured against β-tubulin protein loading control. MPTP-injected mice showed significant decrease of TH protein in Crmp2+/+ mice (n = 4 mice per each condition. **p < 0.01) and reduction of TH protein was not significant in Crmp2KI/KI striatum (n = 4 mice per each condition. p = 0.09). Statistical analysis was carried out using two-way ANOVA test followed by Tukey's test for b, d and unpaired Student's t test for f. Second, we examined the GFAP-positive area using subchronic MPTP injection model. Crmp2+/+ mice showed the increase in this marker after MPTP injection ( Figure  3c ,d, p < 0.05, n = 4 mice). Astrogliosis based on GFAP elevation was also observed in MPTP-injected Crmp2KI/ KI mice which also displayed the increase in GFAP-positive area in Crmp2KI/KI mice after MPTP injection ( Figure  3c ,d, p < 0.05, n = 3 mice). These results suggest that Crmp2+/+ and Crmp2KI/KI mice after MPTP injection (n = 4 mice for Crmp2+/+, n = 3 mice for Crmp2KI/KI. *p < 0.05). Crmp2+/+ mice showed 70.6% ± 31.4% increase in astroglial activation after MPTP injection. Crmp2KI/KI mice also showed 122.3% ± 13.4% increase in astroglial activation after MPTP injection. Statistical analysis was carried out using two-way ANOVA test followed by Tukey's test. inhibition of CRMP2 phosphorylation suppresses microglial activation after MPTP injection.
| MPTP-induced motor impairment was suppressed in Crmp2KI/KI mice
We conducted the rotarod test to examine the impact of genetic suppression CRMP2 phosphorylation in MPTP-induced motor impairment. Rotarod performance was tested at 20 rpm on Day 4, Day 6 and Day 20. Before treatment, four group (n = 7 for each group) showed no difference in their performance (before treatment in Figure 4 ). In MPTP-treated Crmp2+/+ group, there was significant motor impairment in Day 4, 6 and 20 at 20 rpm (p < 0.0001, Figure 4 ). Reduction in rotarod performance was also observed in Crmp2KI/KI mice (p < 0.01, Figure 4) . However, the degree of MPTPinduced motor impairment was significantly suppressed in Crmp2KI/KI mice when compared to control mice (p < 0.05, Figure 4 , Supporting information Figure S2 ).
| DISCUSSION
Previous studies showed that axonal degeneration may play an important role in neurodegenerative disorders including PD and that it may occur at an early stage of these diseases (Braak, Ghebremedhin, Rüb, Bratzke, & Tredici, 2004; Burke & O'Malley, 2013; Cheng & Burke, 2010) . Thus, preventing axonal degeneration may be a potential new approach for therapeutic treatment for these diseases. The elevation of phosphorylation level of CRMP2 through Akt/ GSK3β/CRMP2 pathway is involved in axonal degradation in the study using MPP + -PD model in dopaminergic neuron in vitro (Fang et al., 2014) . However, the role of CRMP2 phosphorylation in axon degeneration in vivo PD model is not tested yet. To study in vivo role of CRMP2 phosphorylation, we first analyzed CRMP2 phosphorylation by site-specific phospho-CRMP2 antibodies after MPTP injection. We conducted this experiment in sub-acute paradigm MPTP injection because in sub-chronic MPTP administration less number of dopaminergic neurons were detected in the SNc (Figure 2a ). Our results indicated Cdk5-mediated CRMP2 phosphorylation occurs in MPTP-induced dopaminergic neuronal damage (Figure 1 ). This result is well matched with previous studies which reported involvement of Cdk5 activation in this process. (Cheung & Ip, 2012; Smith et al., 2003) . However, in present study, the phosphorylation of CRMP2 at T509 in dopaminergic cells did not seem to change after MPTP injection (Figure 1 ). The role of phosphorylation of CRMP2 at different sites in neurodegenerative disorders remains elusive. Then, we tested the effect of genetic inhibition of Cdk5-mediated CRMP2 phosphorylation by using Crmp2KI/KI mice. Although we did not see significant effect on the survival of dopaminergic neurons after MPTP injection, we observed suppression of axonal damage of dopaminergic neurons by MPTP in Crmp2KI/KI mice ( Figure  2 ). Relative preservation of axonal terminal in the striatum with massive decrease in dopaminergic neurons in the SNc in Crmp2KI/KI mice may be explained by compensative effect of remaining dopaminergic neurons. In previous studies, protection of dopaminergic axons with death of dopaminergic cell bodies after 6-OHDA or MPTP injection was also observed in the Wallerian Degeneration Slow (Wld S ) mice, in which axonal degeneration was delayed in many types of neurons (Hasbani & O'Malley, 2006; Sajadi, Schneider, & Aebischer, 2004) . It was indicated that the mechanisms of dopaminergic axons and cell bodies degeneration in PD are separately considered (Cheng & Burke, 2010) . Our results in Crmp2KI/KI mice indicated that phosphorylation of CRMP2 may play a key role in degeneration of dopaminergic axons in PD.
methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced microglia activation was also suppressed in Crmp2KI/KI mice (Figure 3 ). This phenomenon was reminiscent of suppressed F I G U R E 4 Suppressed motor impairment by inhibition of CRMP2 phosphorylation. Time mice spent on the rod rotating at 20 rpm (n = 7 for each group). Data expressed as mean ± SEM. *p < 0.05, ***p < 0.001, ****p < 0.0001. Statistical analysis was carried out for the change in their performance during Day 4, 6 and 20 using two-way ANOVA followed by Tukey's multiple comparison test. Latency to fall (s) immunoreaction in Crmp2KI/KI mice previously observed after spinal cord injury (Nagai, Owada, Kitamura, Goshima, & Ohshima, 2016) . At present, there is insufficient data to discern whether lower immunoreaction is the secondary consequence of reduced neuronal damage or whether blockage of CRMP2 phosphorylation in microglia is involved in the inflammatory suppression. Interestingly, we previously found preserved dopaminergic neurons after MPTP treatment and suppressed microglia activation in male Crmp4−/− mice (Tonouchi, Nagai, Togashi, Goshima, & Ohshima, 2016) . Because CRMP2 and CRMP4 are expressed immune cells (Giraudon et al., 2013; Vuaillat et al., 2008) , examination of the role of CRMPs in immune cells could be a fruitful topic for future studies.
Our studies have showed phosphorylation of CRMP2 plays important role in PD progression, particularly in axon degeneration in accord with its role in spinal cord injury . Inhibitors of CRMP2's upstream molecules can be therapeutic targets for inhibition of CRMP2 phosphorylation. Inhibitors of kinase of CRMP2 such as Cdk5 and GSK3β or inhibitor of selective Sema3A signaling may be therapeutic for spinal cord injury (Kaneko et al., 2006; Renault-Mihara et al., 2011; Tian et al., 2006; Zhang et al., 2014) . However, it may cause potential serious side effects by expressing in other organs (Beurel, Grieco, & Jope, 2014; Lim & Kaldis, 2013; Sakurai, Doçi, & Gutkind, 2012) . Thus, the drug that regulates CRMP2 directly such as LKE (Hensley et al., 2010) is needed for low side effects treatment because CRMP2 are mainly expressed in the brain .
In summary, present study showed significance of phosphorylation of CRMP2 in PD pathophysiology in vivo and suppression of CRMP2 phosphorylation is a putative strategy of the treatment of PD patients.
| EXPERIMENTAL PROCEDURES
| Mouse line and drug treatment
The mice used in the experiments were housed in accordance with the technical protocols for animal experiments approved by the Institutional Animal Care and Use Committee at Waseda University (2015-A-023, 2016-A006, 2017-A027) . The Crmp2KI/KI mice and control Crmp2+/+ mice were obtained by intercrossing Crmp2KI/+ mice and their offspring in 129/Sv × C57BL/6J hybrid background. MPTP (25 mg/kg, i.p.; MKBQ8635V; Sigma) was administered to male mice (22-28 g body weight). Control mice were injected dH 2 O by the same way of MPTP injection, which is a solvent of MPTP solution. The injections and samplings were carried out in two ways as follows. In sub-chronic administration paradigm, the mice were administrated MPTP with an i.p. injection once a day for five consecutive days and were killed 1 day after last injection when dopaminergic neuronal death, microglial and astroglial activations occur. In sub-acute administration paradigm, MPTP injections were conducted once a day for two consecutive days and the mice were fixed 1 day after last injection. We use sub-acute administration paradigm for the analysis of the phosphorylation level of CRMP2 in degenerating dopaminergic neurons because changes of CRMP2 phosphorylation are expected in the process of neural death.
| Western blot analysis
The tissue sampling and Western blotting were carried out as previously described (Tonouchi et al., 2016) . Western blot analysis was carried out on protein samples extracted from striatal tissue. The tissue samples were homogenized in lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 10 mM NaF, 1 mM Na 3 VO 4 , 1% Nonidet P-40, 50 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin) with 1× proteinase inhibitor (Complete; 04 906 845 001; Cat. No; Roche) and 1× phosphatase inhibitor (PhosphoSTOP; Roche), and then the homogenates were centrifuged at 16,300 g for 15 min at 4°. Protein solution was measured with Bio-Rad Protein Assay Dye Reagent Concentrate (500-0006; Bio-Rad Laboratories) and Gene Quant 1300 (GE Healthcare). Protein samples were dissolved on SDS-PAGE gel and transferred to the Immobilon ® -P Transfer Membranes (IPVH07850; Millipore). After the transfer, the membranes were placed in Tris-buffered saline (TBS) containing 0.05% Tween-20 (166-21115; Sigma) with 3% bovine serum albumin (BSA; A7906; Sigma) to block nonspecific binding overnight at 4°. Membranes were incubated at room temperature (RT) for 1 hr with following primary antibodies (anti-TH [rabbit, IgG, 1:1,000; Cat. No. AB152; Millipore] and anti-β-Tubulin [mouse IgG; 1:1,000; Cat. No. 014-25041; Wako] ). Primary antibody incubation was followed by washing in TBS containing 0.05% Tween-20 (TBST) three times for 10 min and then incubating in a second antibody horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG (1:10,000; Cat. No. sc-2004 [rabbit]; sc-2005 [mouse] ; Santa Cruz Biotechnology) at RT for 1 hr. The membranes were washed in TBST three times for 10 min, and then they were developed with diaminobenzidine of Pierce ® Western
Blotting Substrate Plus (NCI32132JP; Thermo) as a color substrate. The membranes were scanned with Luminescent Image Analyzer LAS-3000 (Fujifilm), and the resulting digital images were analyzed quantitatively with ImageJ software (National Institutes of Health).
| Histological analysis
The mice were transcardially perfused with ice-cold 4% paraformaldehyde/PBS solution. Cat. No. A11005; Invitrogen) for 1 hr at RT. After incubation in secondary antibodies, the tissue sections were washed 3 times in 0.01% PBSTr for 10 min. Nuclear staining was carried out with Hoechst 33258 Solution (1:500; H341-10; Dojindo) for 30 min at RT. Finally, the slides were coverslipped with Fluoromount™ Aqueous Mounting Medium (F4680; Sigma-Aldrich), imaged using a confocal microscopy (FV 1000; Olympus). Serial cryosections of midbrain were made at 14 µm and SNc was delineated and the borders were defined, according to anatomical landmarks (Jackson-Lewis, Jakowec, Burke, & Przedborski, 1995; Przedborski et al., 1996) . Sections located in the middle of SNc were subjected to TH or Iba1/GFAP-staining. Counting of the number of the TH-positive neurons in SNc was carried out in three sections from the each mouse brain as previously described (Mochizuki et al., 2001; Prakash, Yadav, Chouhan, & Singh, 2013; Tonouchi et al., 2016) . Microglial activation was evaluated by counting the number of microglia stained with anti-Iba1 antibody around SNc, and astroglial activation was analyzed quantitatively with ImageJ software (National Institutes of Health) by measuring immunoreactivity of GFAP around SNc. Quantitative analysis for the cell level phosphorylation of CRMP2 was conducted by measuring immunoreactivity of pCRMP2 per one TH-positive cell (from 30 to 40 cells) with ImageJ software.
| Behavioral test: rotarod test
As behavioral tests, rotarod was conducted before treatment and during the course of MPTP administration (Day 4) and one day after last MPTP administration (Day 6) and also at the last phase of the study (Day 20) . In rotarod test, mice (n = 7 for each genotype) were placed on the rod to adapt to the environment one day before the test. In the test, each mouse was placed to the rod rotating at 20 rpm (ENV-577/577M: Standalone model, Med. Associates Inc, St. Albans, USA) as described (He et al., 2014) . The latency to fall from the rod was recorded with a maximum score as 180 s at indicated day. Mice were allowed to rest for at least 5 min between each trial. The average latency from three trials on the revolving rod was determined.
| Statistical analysis
Statistical differences between two groups were calculated with an unpaired two-tailed Student's t test. The rest of the data was analyzed using one-way or two-way ANOVA followed by Tukey's multiple comparison test. GraphPad Prism software version 6.0b was used for statistical analysis. Differences were considered significant at p < 0.05.
